E
Outlook Therapeutics, Inc. OTLK
$0.50 -$0.01-1.37% NASDAQ
Recommendation
Prev Close
$0.51
Volume
2,109,505
Avg Vol (90D)
5,298,126
Market Cap
$32.70M
Dividend & Yield
--
52-Week Range
$0.50 - $3.39
P/E (TTM)
--
EPS (TTM)
-$1.62
My Lists My Alerts
Access our Premium Ratings
Get Access
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
Headlines
Analysts' Opinions Are Mixed on These Healthcare Stocks: Medtronic (MDT), Outlook Therapeutics (OTLK) and Johnson & Johnson (JNJ)
1/22/2026 - TipRanks Financial Blog
OTLK Stock Crashes 67% in a Week: Here's What You Need to Know
1/7/2026 - Zacks Investment Research
Outlook Therapeutics Appoints Laura Cantrell as Vice President of Corporate Strategy and ...
1/6/2026 - GuruFocus
Outlook Therapeutics appoints Laura Cantrell as VP, corporate strategy
1/6/2026 - The Fly
Outlook Therapeutics Appoints Laura Cantrell as Vice President of Corporate Strategy and Business Development
1/6/2026 - Globe Newswire
The Narrowing Pathway for Biotech Securities Fraud Claims: Lessons from Outlook Therapeutics
1/4/2026 - TipRanks Financial Blog
Wall Street Zen Downgrades Oncobiologics (NASDAQ:OTLK) to Sell
1/3/2026 - MarketBeat
Outlook Therapeutics price target lowered to $1 from $3 at Chardan
1/2/2026 - TipRanks Financial Blog
Outlook Therapeutics price target lowered by $2 at Chardan, here's why
1/2/2026 - The Fly
Outlook Therapeutics price target lowered by 50c at H.C. Wainwright, here's why
1/2/2026 - The Fly
Futures Blast Off On First Day Of 2026 With Europe, Asia At Records
1/2/2026 - Zero Hedge
Outlook Therapeutics Tanks Over 60% On Another FDA Blow Here's How Retail Is Reacting
1/2/2026 - Stocktwits News Feed
Outlook Therapeutics Stock Sinks After FDA Rejects Eye Drug Again
1/2/2026 - Benzinga
Outlook Therapeutics, Intelligent Bio Solutions And Other Big Stocks Moving Lower In Friday's Pre-Market Session
1/2/2026 - Benzinga
FDA Issues New Setback for Outlook Therapeutics' LYTENAVA
1/2/2026 - TipRanks Financial Blog
Oncobiologics, Inc. (NASDAQ:OTLK) Receives Consensus Rating of "Hold" from Analysts
1/2/2026 - MarketBeat
Outlook Therapeutics (OTLK) Shares Plunge After FDA Setback
12/31/2025 - GuruFocus
Outlook Therapeutics (OTLK) Faces FDA Setback for Wet AMD Treatment
12/31/2025 - GuruFocus
Outlook Therapeutics drops 80% on CRL for BLA for wet AMD asset
12/31/2025 - Seeking Alpha - Healthcare
Outlook Therapeutics drops 80% on CRL for BLA for wet AMD asset
12/31/2025 - SeekingAlpha.com: All News
FDA says cannot approve Outlook Therapeutics ONS-5010 BLA in present form
12/31/2025 - TipRanks Financial Blog
Outlook Therapeutics Inc trading resumes
12/31/2025 - The Fly
FDA says cannot approve Outlook Therapeutics ONS-5010 BLA in present form
12/31/2025 - The Fly
Outlook Therapeutics Provides Regulatory Update on U.S. Food and Drug Administration Review of ONS-5010/LYTENAVA (bevacizumab-vikg) for the Treatment of Wet AMD
12/31/2025 - Globe Newswire
Outlook Therapeutics Inc trading halted, news pending
12/31/2025 - The Fly
Income Statement
Total Revenue (TTM)
$1.41M
EBITDA (TTM)
-$66.94M
EBIT (TTM)
-$67.06M
Net Income (TTM)
-$62.42M
Balance Sheet
Total Assets (Q)
$18.58M
Total Debt (Q)
$30.19M
Total Liabilities (Q)
$50.77M
Book Value Per Share (Q)
-$0.5973
Cash Flow
Cash from Operations (TTM)
-$51.83M
Cash from Investing (TTM)
--
Cash from Financing (TTM)
$44.99M
Net Change in Cash (TTM)
-$6.84M
Filings
Filing Date
Friday, December 19, 2025
Period Date
Tuesday, September 30, 2025
Next Filing
Week of Feb 9 and 13 (est)
Price History
Loading...
Beta
0.68
7-Day Total Return
-10.40%
30-Day Total Return
-75.82%
60-Day Total Return
-62.46%
90-Day Total Return
-52.10%
Year to Date Total Return
-23.79%
1-Year Total Return
-75.34%
2-Year Total Return
-94.33%
3-Year Total Return
-97.71%
5-Year Total Return
-98.15%
52-week Low
Jan 20, 2026 - $0.50
52-week High
Aug 26, 2025 - $3.39
Valuation
Market Cap
$32.70M - Nano Cap
Enterprise Value
$54.81M
Price/Sales (TTM)
17.06
Price/Book (Q)
-0.85
Dividends and Shares
Shares Outstanding
47.19M
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
outlooktherapeutics.com
Phone Number
609 619 3990
Address
111 S. Wood Avenue
Iselin, NJ 08830
Country
United States
Year Founded
2010
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for ophthalmic indications. Its lead product... more
NASDAQ 01/23/2026 4:00PM Eastern Quotes delayed